TNYA Tenaya Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1858848 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-8.0%
TTM EPS YoY36.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-148.2%
ROA-112.1%
ROIC (approx.)-1,156.6%
Asset turnover—
Leverage & solvency
Liabilities / assets28.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio-52.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $68.61M | $86.74M |
| SG&A expense | $24.72M | $29.21M |
| Operating income | -$93.33M | -$115.95M |
| Pretax income | -$90.60M | -$111.13M |
| Income tax | $0 | $0 |
| Net income | -$90.60M | -$111.13M |
| EBITDA | -$84.89M | -$107.48M |
| EPS (basic) | -0.59 | -1.31 |
| EPS (diluted) | -0.59 | -1.31 |
| Weighted avg. shares (diluted) | 152.97M | 84.82M |
| Balance sheet | ||
| Cash & equivalents | $100.55M | $4.32M |
| Short-term investments | — | $57.12M |
| Current assets | $105.59M | $67.38M |
| PP&E, net | $27.67M | $35.86M |
| Total assets | $146.92M | $119.94M |
| Current liabilities | $15.44M | $15.97M |
| Total liabilities | $23.66M | $27.09M |
| Shareholders' equity | $123.27M | $92.85M |
| Shares outstanding | 216.76M | 86.54M |
| Cash flow statement | ||
| Operating cash flow | -$68.26M | -$90.50M |
| Capital expenditure | $618,000 | $1.02M |
| Free cash flow | -$68.88M | -$91.53M |
| Investing cash flow | $56.08M | $1.13M |
| Financing cash flow | $108.41M | $47.75M |
| Depreciation & amortization | $8.44M | $8.47M |
| Stock-based compensation | $13.05M | $16.50M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.